Australia's Sigma seeks better offer from Aspen

Embattled Australian drug maker Sigma Pharmaceuticals said it will work with South Africa's Aspen Pharmacare to improve its A$648 million ($567 million) bid, but did not endorse the offer and declined to extend Aspen's exclusivity.